Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program

Core Insights - Kura Oncology, Inc. is hosting two virtual investor and analyst events to showcase its farnesyl transferase inhibitor (FTI) program, emphasizing its leadership in targeting cancer signaling pathways for solid tumors and hematologic malignancies [1][5] Event Summaries - The first event on September 16, 2025, will focus on the preclinical program of FTIs, discussing their synergistic combinations with targeted therapies such as tyrosine kinase inhibitors, RAS inhibitors, and PI3K alpha inhibitors, highlighting their potential to transform treatment for solid tumors [2] - The second event on October 18, 2025, will present clinical data from the 2025 ESMO Congress, including the first clinical insights from KO-2806, Kura's next-generation FTI, which aims to address resistance mechanisms in cancer [3] ESMO Congress Presentations - Kura will present preliminary results from the FIT-001 phase 1 trial of KO-2806 in combination with cabozantinib for renal cell carcinoma on October 18, 2025 [4] - A phase 1 study of KO-2806 as monotherapy in advanced solid tumors will be presented on October 19, 2025 [4] - Results from the KURRENT-HN trial involving tipifarnib and alpelisib in recurrent/metastatic head and neck squamous cell carcinoma will be shared on October 20, 2025 [4] Company Overview - Kura Oncology is a clinical-stage biopharmaceutical company focused on precision medicines for cancer, with a pipeline targeting cancer signaling pathways and addressing high-need hematologic malignancies and solid tumors [5] - The company is developing ziftomenib, a menin inhibitor for acute myeloid leukemias, and is advancing both menin and farnesyl transferase inhibition strategies to tackle resistance mechanisms in solid tumors [5][6]